| Autor: |
Ashley Martucci, Rebecca L. Blanchard, Deborah Panebianco, Maria Gutierrez, M. Gail Murphy, Christopher Lines, John Palcza, Cynthia Miller-Stein, Ronda K. Rippley, Tae H. Han |
| Rok vydání: |
2010 |
| Předmět: |
|
| Zdroj: |
Archives of Drug Information. 3:55-62 |
| ISSN: |
1753-5174 |
| DOI: |
10.1111/j.1753-5174.2010.00031.x |
| Popis: |
Introduction. Telcagepant (MK-0974) is a novel, orally active and selective CGRP receptor antagonist being investigated for acute treatment of migraine. Early clinical data suggested greater than dose proportional increases in exposure following oral administration. The aim of the present studies was to definitively characterize the oral and IV dose proportionality of telcagepant. Methods. Healthy adult subjects were enrolled in two separate open-label randomized dose proportionality studies: 1) single oral dose crossover from 50 to 600 mg (N = 19); 2) single IV dose parallel group from 5 to 250 mg (N = 10 per dose). Blood samples were collected at time points from 0 to 48 hours postdose. Results. Telcagepant was rapidly absorbed with a Tmax of approximately 1 to 2 hours after oral administration. The terminal half-life was approximately 8 to 9 hours after IV dosing and approximately 4 to 7 hours after oral dosing. Oral administration of telcagepant resulted in greater than dose proportional increases in exposure, while IV administration resulted in approximately dose proportional increases in exposure. Conclusions. Telcagepant was generally well tolerated. Oral telcagepant exhibits non-linear pharmacokinetics. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text